Fidaxomicin approved for Cdiff treatment

Dificid (fidaxomicin) was approved by the FDA for treatment of Cdiff. In randomized trials, it was found to have similar efficacy to vancomycin, but with fewer relapses. However, due to high cost, it may be best reserved for treatment relapses after metronidazole and/or vancomycin failures (FDA site)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment